TSGF、NSE和CYFRA-21-1联合检测在肺癌诊治中的应用

Assessment of Serum TSGF, NSE and CYFRA-21-1 in Lung Cancer

目的:探讨TSGF、NSE和CYFRA-21-1 3种血清肿瘤标志物单独及联合检测在肺癌诊断、手术治疗效果评价及转移复发监测中的应用价值;方法:显色法测定TSGF、酶联免疫吸附法测定NSE和放射免疫法测定CYFRA-21-1,共测定50例健康成人及36例不同分型的肺癌患者的血清标本,并对其中24例患者进行了术后3个月～2年的随访监测。结果:健康人组TSGF为53.7±5.7U/mL,NSE为2.7±0.7ng/mL,CYFRA-21-1为1.4±0.8μg/mL。肺癌患者各型3项血清肿瘤标志物中的任何一项均较健康人组有显著增高(P<0.05),其敏感性与病理分型相关。术前TSGF为76.4±7.6U/mL,NSE为15.2±6.1ng/mL,CYFRA-21-1为11.2±8.6μg/m,术后3项肿瘤标志物检测的数值较术前的明显下降(P<0.05);而当术后转移复发时明显增高,与术前差异无显著意义(P>0.05)。3项血清肿瘤标志物经组合后,敏感性显著提高。结论:TSGF、NSE和CYFRA-21-1对肺癌的诊断、疗效判断及转移或复发监测有意义。TSGF、CYFRA-21-1二者联合检测可作为鳞癌诊治的首选标志。TSGF、NSE二者联合检测可作为小细胞性肺癌首选指标。

Objective:To evaluate the application of three tumor markers: TSGF, NSE and CYFRA-21-1 in monitoring lung cancer. Methods: TSGF was detected by chemical metric analysis, NSE by ELISA technology, and CYFRA-21-1 by radioimmunoassay (RIA) . 50 healthy adults and 36 patients with lung cancer were detected. Results: In the healthy group, TSGF were 53.7 ± 5.7 U/ mL,NSE were 2.7±0.7 ng/mL, CYFRA-21-1 were 1.4±0.8 f66g/mL, respectively. The levels of the three tumor markers in patients with lung cancer were significantly higher than those in the healthy group ( P < 0.05) . Before operation, TSGF was 76.4 ± 7.6 U/mL,NSE was 15.2 ± 6.1 ng/mL and CYFRA-21-1 was 11.2 ± 8.6μg/mL, respectively. After operation, a marked decrease of these values was observed ( P < 0.05) . The sensitivity was greatly enhanced when the three marks were analyzed combinedly. Conclusion: The three tumor markers are of partly value in detecting lung cancer. It can greatly raise the sensitivity and validity by the use of their appropriate combination. Combined TSGF and CYFRA-21-1 to diagnose squamous cell carcimotna is more effective than others, and so as combined TSGF and NSE to detect small cell lung cancer.